Atea Pharmaceuticals announces presentation of data on BEM, RZR

Atea Pharmaceuticals (AVIR) announced the presentation of new modeling data predicting that the Company’s combination regimen of bemnifosbuvir, BEM, a nucleotide analog polymerase inhibitor, and ruzasvir, RZR, an NS5A inhibitor, achieved near-complete inhibition of both viral replication and assembly and secretion into the bloodstream, with a modeled time to cure of approximately 7 to 8 weeks. These findings support the fixed-dose combination, FDC, regimen of BEM and RZR as a potential best-in-class, convenient, short-duration treatment of hepatitis C virus, HCV, further validating the Company’s Phase 2 study results, which demonstrated that the combination regimen, after 8 weeks of treatment, achieved sustained virologic response rates at 12 weeks post-treatment, SVR12, of 98% in the per-protocol treatment-adherent patient population and 95% in patients regardless of adherence. These modeling data will be presented at The Liver Meeting 2025, the annual meeting of the American Association for the Study of Liver Diseases, AASLD, taking place November 7-11 in Washington, DC.